Abstract
Sudden non-traumatic death in young athletes is due to underlying congenital/inherited cardiac diseases in over 80% of cases. The two commonest conditions leading to sudden cardiac death in athletes below the age of 25 years are hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC).
Hypertrophic cardiomyopathy is caused by mutations in genes, which code for sarcomeric contractile proteins. It can present with symptoms such as palpitation, presyncope or syncope. In a small number of cases, sudden death is the first clinical manifestation of the condition. It is well established that HCM accounts for over half of all cases sudden cardiac death in young individuals below 25 years of age. The management of HCM broadly encompasses symptom control, familial evaluation and the prevention of sudden death.
Arrhythmogenic right ventricular cardiomyopathy, similarly, is a genetic disorder of the heart muscle and leads to symptoms such as palpitation and syncope and more rarely sudden death. The diagnosis of ARVC is most likely underestimated due to the lack of a single diagnostic test and subtle morphological changes in some cases. The diagnosis is based on clinical and family history and non-invasive investigations.
The physiological adaptations seen in some athletes, as a response to physical training, may resemble phenotypically mild forms HCM and ARVC. Therefore, a diagnostic algorithm enabling this differentiation would be of importance especially bearing in mind the consequences of a misdiagnosis.
Similar content being viewed by others
References
Paffenbarger RS Jr, Hyde RT, Wing AL, Lee I-M, Jung DL, Kampert JB. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Eng J Med1993;328:538–545.
Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Eng J Med 1993;328:533–537.
Kushi LH, Fee RM, Folsom AR, Mink PJ, Anderson KE, Sellers TA. Physical activity and mortality in postmenopausal women. JAMA1997;277:1287–1292.
Slattery ML, Jacobs DR, Nichmann MZ. Leisure time physical activity and coronary artery disease. The US railroad study. Circulation1989;79:304–311.
Morris JN, Everitt MG, Pollard R, Chave SPW, Semmence AM. Vigorous exercise in leisure-time: Protection against coronary heart disease. Lancet1980;2:1207–1210
Siskovick DS, Weiss NS, Fletcher RH. The incidence of primary cardiac arrest during vigorous exercise. N Eng JMed1994;311:874–877.
Leon AS, Connett J, Jacobs DR Jr,Rauramaa. Leisure-time physical activity levels and risk of coronary heart disease and death: The multiple risk intervention trial. JAMA1987; 258:2388–2395.
Albert CM, Mittleman MA, Chae CU, Lee I-M, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Eng J Med2000;343:1355–1361.
Maron BJ. Sudden death in athletes: Lessons from the Hank Gathers affair. N Eng J Med1993;329:55–57.
Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE. Sudden death in young athletes. Circulation1980;62:218–229.
Maron BJ, Epstein SE, Roberts WC. Causes of death in competitive athletes. J Am Coll Cardiol1986;7:204–214.
Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: Clinicopathological correlations in 22 cases.AmJMed1990;89:588–596.
Burke AP, Farb A, Virmani R. Causes of sudden death in athletes. Cardiol Clin1992;10:303–317.
Opie LH. Sudden death and sport. Lancet1975;1:263–266.
Northcote RJ, Ballantyne D. Sudden cardiac death in sport. British Medical Journal Clinical Research Edition 1983;287:1357–1359.
Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Non-traumatic sports death in high school and college athletes. Med Sci Sports Exerc1995;27:641–647.
James TN, Froggat P, Marshall TK. Sudden death. Ann Intern Med 1982;106:168–170.
Furnalleno F, Bettini R, Cozzi F, et al. Ventricular arrhythmias and sudden death in athletes. Ann N Y Acad Sci1984;427:253–279.
Thiene G, NavaA, Corrado D, Rossi L, Pennelli L. Right ventricular cardiomyopathy and sudden death in young people. N Eng J Med1988;318:178–180.
Epstein SE, Maron BJ. Sudden death and the competitive athlete: Perspectives on preparticipation screening studies. J Am Coll Cardiol1986;6:1189–1190.
Ades PA. Preventing sudden death. Physician and Sportsmedicine1992;20:75–79.
Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic and pathological profiles.JAMA 1996;276:199–204.
Report of the WHO/ESFC task force on the definition and classification of cardiomyopathies. Circulation1996;93:841–842.
Maron BJ, Gardin JM, Flack JM. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in theCARDIA study. Circulation1995;92:785–789.
McKenna WJ, Watkins HC. In: Scriver CR, Beaudet AL, Sly WS, Valle E, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th ed., Vol III. New York: McGraw-Hill, 1995:4523–4572.
Davies MJ. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br Heart J1984;51:361–363.
McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. Influence on prognosis. Br Heart J1981;46:168–172.
Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A twodimensional echocardiographic study. J Am Coll Cardiol1983;2:437–444.
Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, 2-dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418–428.
McKenna WJ, Elliott PM, Topol EJ, eds. In: Comprehensive Cardiovascular Medicine, Vol. I. Philadelphia: Lipincott-Raven, 1998:775–798.
Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med1997;336:775–785.
McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: Assessment of patients at high risk. Circulation 1989;80:1489–1492.
McKenna WJ, Deanfield J, Faruqui A. Prognosis of hypertrophic cardiomyopathy: Role of age and clinical electrocardiographic and haemodynamic features. Am J Cardiol 1978;41:1133–1140.
Burke AP, Farb A, Virmani R. Sports-related and non-sports related sudden cardiac death in young adults. Am Heart J 1991;121:568–575.
Huston TP, Puffer JC, McMillan R. The athletic heart syndrome. N Eng J Med1985;313:24–32.
Pellicia A, Maron BJ, Spataro A, Proschan MA, Spiroto P. The upper limit of physiological hypertrophy in highly trained elite athletes. N Eng J Med1991;324:295–301.
Maron BJ, Pellicia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athletes heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596–1601.
Lewis J. Considerations for racial differences in the athlete's heart. Cardiol Clin1992;10:329–333.
Sharma S, Whyte G, Elliott PM, et al. Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med1999;33:319–324.
Mitchell JH, Maron BJ, Epstein SE. 16th Bethesda Conference: Cardiovascular abnormalities in the athlete. Recommendations regarding eligibility for competition. J Am Coll Cardiol1985;6:1186–1232.
McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Am J Cardiol1981;48:252–257.
Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med2000;342:365–373.
Oakley DG, Oakley CM. Significance of abnormal ECGs in highly trained athletes. Am J Cardiol1982;50:985–989.
Shapiro LM. Physiological left ventricular hypertrophy. Br Heart J1984;52:130–135.
Roeske WR, O'Rourke RA, Klein, Leopold G, Karliner JS. Non-invasive evaluation of ventricular hypertrophy in professional athletes. Circulation1976;53:286–292.
Jones S, Elliott PM, Sharma S, McKenna WJ, Whipp BJ. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart1998;80:60–67.
Sharma S, Elliott PM, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol2000;86(2):162–168.
Ehsani AA, Hagberg JM, Hickson RC. Rapid changes in left ventricular dimensions and mass in response to physical conditioning and deconditioning. Am J Cardiol1978;42:52–56.
McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task force of theWorking Group Myocardial and Pericardial Disease of the European Society of Cardiology and the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J1994;71:215–218.
Laurent M, Descaves C, Biron Y, Deplace C, Almange C, Daubert JC. Familial form of arrhythmogenic right ventricular dysplasia. Am Heart J1987;113:827–829.
Nava A, Thiene G, Canciani B, et al. Familial occurrence of right ventricular dysplasia. A study involving nine families. J Am Coll Cardiol1988;12:1222–1228.
Ruder MA, Winston SA, Davis JC, Abbot JA, Eldar M, Scheinmann L. Arrhythmogeni right ventricular dysplasia in a family. Am J Cardiol1985;56:799–800.
McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakaglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet2000;355:2119–2124.
Marcus FI, Fontaine G, Guiraudon G, et al. Right ventricular dysplasia. A report of 24 adult cases. Circulation 1982;65:384–398.
Rossi P, Massumi A, Gillette P, Hall RJ. Arrhythmogeni right ventricular dysplasia: Clinical features, diagnostic techniques and current management. Am Heart J1982;3:415–420.
Thiene G, Nava A, Corrado D, Rossi L, Pennelli L. Right ventricular cardiomyopathy and sudden death in young people. N Eng J Med1988;318:129–133.
Maron BJ. Right ventricular cardiomyopathy: Another cause of sudden death in the young. N Eng J Med1988; 318:178–180.
Nava A, Thiene G, Canciani B, et al. Clinical profile of concealed form of arrhythmogenic right ventricular cardiomyopathy presenting with apparently idiopathic ventricular tachycardia. Int J Cardiol1992;35:195–206.
Buxton AE, Waxman HL, Marchlinski FE, Simon MB, Cassidy D, Josephson ME. Right. ventricular tachycardia: Clinical and electrocardiographic characteristics. Circulation 1983;68:917–927
Kisslo J. Two dimensional echocardiography in arrhythmogenic right ventricular dysplasia. Eur Heart J1989;10 (suppl D):42–45.
Chiddo A, Locuratolo N, Gaglione A, et al. Right ventricular dysplasia: Angiographic study. Eur Heart J1989;10 (suppl D):42–45.
Robertson JH, Brady GH, German LD. Comparison of two dimensional echocardiographic and angiographic findings in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol1985;55:1506–1508.
Casolo GC, Poggesi I, Boddi M, et al. ECG-gated magnetic resonance imaging in right ventricular dysplasia. Am HeartJ1987;113:1245–1248.
Ricci C, Longo R, Pagnan L, et al. Magnetic resonance imaging in right ventricular dysplasia. Am J Cardiol1992;70:1589–1595.
Breihardt G, Wichter T, Haverkamp W, et al. Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome or no structural heart disease. Am Heart J1994;4:1151–1158.
Hauser AM, Dressendorfer RH, Vos M, Hashimoto T, Gordon S, Timmis GC. Symmetric cardiac enlargement in highly trained endurance athletes: A two dimensional echocardiographic study. Am Heart J1985;109:1038–1044.
Maron BJ, Bodison SA, Wesley YE, Tucker E, Green KJ. Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. J Am Coll Cardiol 1987;10:1214–1221.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Firoozi, S., Sharma, S., Hamid, M.S. et al. Sudden Death in Young Athletes: HCM or ARVC?. Cardiovasc Drugs Ther 16, 11–17 (2002). https://doi.org/10.1023/A:1015307229339
Issue Date:
DOI: https://doi.org/10.1023/A:1015307229339